The Blogs:
Nov 28, 2011
Majority Sees BiovaxID Gaining Faster Acceptance if Approved Than Provenge
Alex Philippidis
BioVest’s immunotherapy BiovaxID®, if approved for follicular lymphoma, will likely gain acceptance on the market more quickly than the Dendreon’s prostate cancer vaccine Provenge, which was the first to recieve marketing approval, according to an overwhelming majority of responders to GEN's recent survey. By a consideral margin (72.2% to a 10.2% margin, with 17.6% undecided), respondents believe that BioVest will not face the manufacturing and reimbursement issues Dendreon has had to deal with. GEN surveyed readers three weeks after Dendreon’s Nov. 2 prediction of “modest” fourth-quarter sales of Provenge, with November sales expected to be slightly below October’s. Biovest’s president Samuel S. Duffey has said his company’s production time frames are not as limited as those of Dendreon.
Related content
Subscription center
BACK TO TOP